Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world post-marketing safety study of lobaplatin in 30,000 cancer patients
ChiCTR2100044341Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Jan 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lobaplatin in cancer, sponsored by Chongqing University Cancer Hospital. Primary endpoint: Safety. Started Jan 2021; status: recruiting.
02
Drugs
lobaplatin
03
Conditions
cancer
Beyond the preview
Go deeper on ChiCTR2100044341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044341.